Biomarker identification and pathway analysis by serum metabolomics of childhood acute lymphoblastic leukemia

Bai, Y.; Zhang, Haitao; Sun, Xiaohan; Sun, Chongde; Ren, Lihong

doi:10.1016/j.cca.2014.05.022

Cited by 39 publications

(34 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few recent studies regarding leukaemia have been done, for instance, tumour microenvironment for childhood ALL has been done using high‐resolution magnetic resonance spectrometry (MRS) and gas chromatography mass spectrometry (GC‐MS) for fatty acids analysis . Another paediatric ALL biomarker study was done using ultra pressure liquid chromatography . A metabonomic study for de novo AML was also done .…”

Section: Introductionmentioning

confidence: 99%

SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules

Musharraf

Siddiqui

Shamsi

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

Acute leukaemia (AL) is a critical neoplasm of white blood cells. Diagnosing AL requires bone marrow puncture procedure, which many patients do not consent to for it is invasive. Hence sensitive and specific early diagnostic biomarkers are essential for non-invasive diagnosis, new therapeutics and improving the disease prognosis. To differentiate the metabolic alterations associated with acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), we investigated serum of ALL and AML patients in comparison with two controls using gas chromatography coupled with triple quadrupole tandem mass spectrometry and multivariate statistical analysis. Twenty seven out of 1425 metabolites were found differentiative among ALL, AML, aplastic anaemia (APA) patients and healthy control using p-value ≤ 0.001. ALL is the most dissimilar group from other three groups as in hierarchical clustering showed 72.1% dissimilarity. Model generation using PLSDA gave an overall accuracy of 91.9%. This study helps in metabolic fingerprinting of control and disease serum at high significance levels and could be used for early diagnosing of AL. Based on pathways analysis, fatty acid metabolism is deregulated in patients with AL and may represent an underlying metabolic pathway associated with disease progression. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules

Musharraf

Siddiqui

Shamsi

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…etabolomic studies using time-of-flight mass spectrometry have become important means to discover novel biomarkers in human diseases and, in particular, to elucidate the associated biochemical abnormalities [1][2][3][4][5]. In the biomedical field, it offers the possibility to evaluate small metabolites (1500 Da and less) in biological fluids, tissue extracts, or cells of patients compared with gender-and age-matched healthy controls.…”

mentioning

confidence: 99%

Metabolomic Discovery of Novel Urinary Galabiosylceramide Analogs as Fabry Disease Biomarkers

Boutin

Auray‐Blais

2015

J. Am. Soc. Mass Spectrom.

View full text Add to dashboard Cite

Abstract. Fabry disease is an X-linked, complex, multisystemic lysosomal storage disorder presenting marked phenotypic and genotypic variability among affected male and female patients. Glycosphingolipids, mainly globotriaosylceramide (Gb 3 ) isoforms/analogs, globotriaosylsphingosine (lyso-Gb 3 ) and analogs, as well as galabiosylceramide (Ga 2 ) isoforms/analogs accumulate in the vascular endothelium, nerves, cardiomyocytes, renal glomerular and tubular epithelial cells, and biological fluids. The search for biomarkers reflecting disease severity and progression is still on-going. A metabolomic study using quadrupole time-of-flight mass spectrometry has revealed 22 galabiosylceramide isoforms/analogs in urine of untreated Fabry patients classified in seven groups according to their chemical structure: (1) Saturated fatty acid; (2) one extra double bond; (3) two extra double bonds; (4) hydroxylated saturated fatty acid; (5) hydroxylated fatty acid and one extra double bond; (6) hydrated sphingosine and hydroxylated fatty acid; (7) methylated amide linkage. Relative quantification of both Ga 2 and Gb 3 isoforms/analogs was performed. All these biomarkers are significantly more abundant in urine samples from untreated Fabry males compared with healthy male controls. A significant amount of Ga 2 isoforms/analogs, accounting for 18% of all glycosphingolipids analyzed (Ga 2 +Gb 3 and respective isoforms/analogs), were present in urine of Fabry patients. Gb 3 isoforms containing saturated fatty acids are the most abundant (60.9%) compared with 26.3% for Ga 2 . A comparison between Ga 2 isoforms/analogs and their Gb 3 counterparts also showed that the proportion of analogs with hydroxylated fatty acids is significantly greater for Ga 2 (35.8%) compared with Gb 3 (1.9%). These results suggest different biological pathways involved in the synthesis and/or degradation of Gb 3 and Ga 2 metabolites.

show abstract

“…Because of the lack of adequate initial symptoms, the clinical diagnosis of chALL requires a bone marrow biopsy/aspiration which is completely invasive, especially for children (17). Considering the laborious and painful nature of bone marrow biopsy/aspiration, reliable biomarkers for disease diagnosis and monitoring is appealing and of paramount importance (18).…”

Section: Introductionmentioning

confidence: 99%

Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia

et al. 2020

View full text Add to dashboard Cite

Biomarkers are biological molecules found in body fluids or tissues, which can be considered as indications of a normal or abnormal process, or of a condition or disease. There are various types of biomarkers based on their application and molecular alterations. Treatment-sensitivity or drug resistance biomarkers include prognostic and predictive molecules with utmost importance in selecting appropriate treatment protocols and improving survival rates. Acute lymphoblastic leukemia (ALL) is the most prevalent hematological malignancy diagnosed in children with nearly 80% cure rate. Despite the favorable survival rates of childhood ALL (chALL), resistance to chemotherapeutic agents and, as a consequence, a dismal prognosis develops in a significant number of patients. Therefore, there are urgent needs to have robust, sensitive, and disease-specific molecular prognostic and predictive biomarkers, which could allow better risk classification and then better clinical results. In this article, we review the currently known drug resistance biomarkers, including somatic or germ line nucleic acids, epigenetic alterations, protein expressions and metabolic variations. Moreover, biomarkers with potential clinical applications are discussed.

show abstract

Biomarker identification and pathway analysis by serum metabolomics of childhood acute lymphoblastic leukemia

Cited by 39 publications

References 36 publications

SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules

SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules

Metabolomic Discovery of Novel Urinary Galabiosylceramide Analogs as Fabry Disease Biomarkers

Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About